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Skin problems associated with pegylated liposomal doxorubicin-more than 
palmoplantar erythrodysesthesia syndrome. 
Abstract   
Background. Liposomal pegylated doxorubicin is an encapsulated form of doxorubicin, 
with an improved pharmacokinetic profile and the ability to selectively accumulate into 
tumor tissue. As a result, tolerated dose of the drug can be increased followed by the  
reduced incidence of neutropenia and cardiotoxicity in comparison to doxorubucin 
treatment. However, common adverse dose-schedule limiting effect of the treatment is 
palmoplantar erythrodysesthesia syndrome. 
Design. In this retrospective study we included six patients hospitalised in the University 
Hospital of Zurich during the last 2 years, in connection with side effects caused by 
pegylated liposomal doxorubicin. These patients received this chemotherapeutic agent for 
treatment of various malignancies such as breast cancer, ovarian cancer, mycosis fungoides 
and cutaneous B-cell lymphoma.  
Results. Three of six patients in this study developed classical palmoplantar 
erythrodysesthesia, one developed palmoplantar erythrodysesthesia associated with 
extensive bullous disease, one developed eruption of lymphocyte recovery syndrome and 
one developed intertrigo like dermatitis with stomatitis. 
Conclusion.  Pegylated liposomal doxorubicin induces various skin reactions including 
palmoplantar erythrodysesthesia syndrome. However the exact clinical presentation might 
depend on pre-existing skin diseases. 
Key words: eruption of lymphocyte recovery, hand foot syndrome, palmoplantar 
erythrodysesthesia, pegylated liposomal doxorubicin, skin toxicities, stomatitis, 
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Introduction  
Delivery systems have been developed to exploit tumor microphysiology and have aimed at 
improving the tropism of chemotherapeutic agent toward tumor cells [1].Therefore 
macromolecular carriers have been used during the past years providing the single drugs 
with specific characteristics, such as long circulating time capacity, preferential 
extravasation and accumulation in tumor stroma. Liposomal anthracyclines, such as 
pegylated liposomal doxorubicin (PLD) have accomplished considerable and prolonged 
circulation within the body based upon unique drug encapsulation, which in turn results in 
significant anticancer activity with reduced adverse effects, such as cardiotoxicity and 
neutropenia [2]. 
PLD is an encapsulated into polyetyelene-glycol coated liposomes variant of doxorubicin 
with a reduced uptake by the reticulo-endothelial system. The volume of distribution of this 
drug is close to blood volume and the area under the concentration-time curve (AUC) is 
increased at least 60 fold compared with free doxorubicin [3]. PLD has an eliminated  half-
life around 40-60 hours in human body and circulation time of 2-3 weeks in the blood and 
the drug remains encapsulated in the liposomes during this time [4]. 
PLD acts in a completely different manner when compared to doxorubicin in a non 
liposomal form. After extravasation into tumor tissue, liposomes remain within tumor cells. 
but they do not interact with plasma proteins and mononuclear phagocytes. Consequently, 
liposomes undergo enzymatic degradation, which leads to the release of the drug into the 
tumor tissue. During encapsulation within the liposomes, the drug is not bioavailable, hence 
has no anti-tumor effect and thus no therapeutic ability. On the opposite side, the therapeutic 
results of the medication itself and differences in these may not vary much compared to 
doxorubicin when the liposomes have not yet reached to the target tissues [5].Therefore 
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there is a correlation between efficacy and toxicity of liposomal doxorubicin and the 
different liposomal leakage rates.Liposomes with the best therapeutic activity are those with 
the slowest drug release rate [6]. 
The pegylated liposomal form of doxorubicin has been investigated and is used today for the 
treatment of metastatic breast cancer, aggressive Non-Hodgkin lymphoma, non small cell 
lung cancer, multiple myeloma, gastrointestinal malignancies [7]. Moreover, it is more and 
more often accepted as a treatment option for the acquired immunodeficiency syndrome-
related Kaposi sarcoma [8] and the refractory ovarian cancer [9]. There are many side effects 
reported, which are connected to PLD treatment, nevertheless, skin toxicities are the most 
important dose limiting side effects. 
We report on 6 consecutive patients with different mallignancies which were referred to or 
treated by the Department of Dermatology of Zurich University hospital with PLD and in 
turn developed cutaneous side effects, including palmoplantar erythrodysesthesia syndrome 
(PPE), also called hand foot syndrome (HFS) or acral erythema (AE). PPE is characterised 
as a patchy erythema of hands and soles, whose primary lesions can sometimes become 
painful, can lead to erosions and to desquamation, ulceration, blister formation and can also 
cause functional limitation during daily activity.  
 
Materials and methods 
Medical records of six patients treated with PLD at the University hospital of Zurich from 
2005 until 2007, were retrospectively reviewed. Laboratory data including histological 
findings and clinical information of the skin manifestation such as clinical symptoms, 
location and severity of clinical signs, as well as treatment regimen were collected. Toxicity 
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was graded using the basic scale from the common toxic effects criteria of the National 
Cancer Institute for evaluation of the skin lesions (Table 1) [10]. 
All six patients were Caucasian women with the age range from 23 to 73 years. They 
received PLD in different doses-schedules as a treatment for different malignancies: three of 
them for metastasized breast cancer, one for ovarian cancer, one for tumor stage mycosis 
fungoides [11] and one for cutaneous B-cell lymphoma (Table 2). All six patients had 
diagnosed disease evaluated with standard criteria. Dermatologic examination was 
conducted at all cases and any evidence of skin toxicity was classified and documented.  
Before receiving PLD five of six patients were treated with at least one chemotherapeutic 
agent. Only one patient had received anthracyclines in the past, with no reported side effect. 
Also no allergic side effects occurred during infusion of PLD. PLD was administered as a 1-
2 hours intravenous infusion. The cycles were repeated every four weeks, except in two 
cases, in which they repeated every two weeks. One patient received oral corticosteroids, as 
prophylactic treatment of PPE before the infusion. 
Results 
Clinical presentations and severity 
Three of six patients in this study developed classical PPE, one PPE associated with bullous 
disease on pre-existing scars due to prurigo nodularis, one developed eruptions of 
lymphocyte recovery (ELR) and one showed intertrigo-like dermatitis with stomatitis. In 
five of  six patients the manifestations were located on the palms and soles, in three patients 
they were located also at the intertriginous areas of the body and one showed infiltration of 
the oral mucosa (Table 2). Two of the patients developed Grade III skin lesions, one of 
which was compatible with PPE and the other with ELR. One of the patients developed 
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Grade IV PPE (Table 2). We now would like to present two of the six clinical cases, based 
on their special clinical features. 
Clinical case1 
A 73-year old woman with breast cancer first diagnosed in 2003 with bone metastases, 
received 5 cycles of PLD, 50 miligramme per square metre of body surface area (mg/ m2 ) 
every four weeks for five cycles , two years after she underwent bilateral mastectomy. She 
was diagnosed with prurigo nodularis in 2000. Prurigo nodularis is a chronic eczematous 
process of unknown aetiology, characterized by a papulonodular pruriginous eruption and 
subsequent scar formation [12]. Five days after the last infusion of PLD, patient presented 
with a generalised erythema with erosions and bullae formation, preferentially at the sites of 
mechanical pressure. Skin eruptions were not restricted to hands and feet areas, but they 
were spread over the whole body including the capillitium and the axilla region. Due to 
prurigo nodularis patient also developed later bullae in the regions of preexisted scars and 
traumatized skin areas (Fig. 3). Tenderness, oedema as well as painful erythema and 
desquamation on both palms and soles were also observed (Fig. 1 and 2 ) 
Two weeks after the fifth cycle of PLD the patient was diagnosed with cardiomyopathy with 
left ventricular ejection fraction (LVEF) of 31 per-cent ( %). Cardiologic assessment was 
made by clinical examination, serial echocardiogram (ECG) and the measurement of LVEF 
obtained by echocardiography. Due to lack of previous clinical data, the unknown initial 
LVEF and pre-existing atrial fibrilation (AF), no secure correlation to the PLD therapy could 
be determined. 
Clinical case 2 
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A 40 year-old woman was diagnosed with breast cancer in 1989 and underwent bilateral 
mastectomy in the same year. During the following years the patient received multiple 
cycles of other chemotherapeutic agents, including anthracyclines. In 2006 lung metastases 
were diagnosed and patient was treated with capecitabine until April 2007. A few weeks 
later she received PLD 50mg/m2 infused in three cycles. One week after the third cycle,  
patient developed painful redness with desquamation, vesicules, macules and papules 
confined to hands and soles.The skin of the hands begun to peel. A few days later the 
maculopapular rash was spread to the axilla, trunk and extremities and patient had 
difficulties in picking up objects with her fingers, due to swelling and pain. At this stage,  
patient was hospitalised and low fever was recorded. 
The diagnosis of ELR was established based on the histological findings, the subsequent 
blood tests which showed excessive lymphopenia and decreased (white blood cells) WBC 
coinciding with the rash, the negative immunofluorecence and the clinical signs.  
Histological features 
In four of six patients to evaluate the clinical diagnosis skin biopsies were performed in two 
papular, one papulovesiclar and one erythematous lesions. In connection with PPE, biopsies 
revealed unspecific changes such as mild spongiosis, sup-epidermal oedema, perivascular 
lymphocytic infiltration, dilated blood vessels, keratinocyte necrosis and presentation of 
eosinophils in the dermis. In one case there was also evidence of neutrophilic infiltrates of 
the sweat glands, compatible with neutrophilic eccrine hidradenitis. In the case of ELR, 
biopsy showed an atrophic epidermis with apoptotic keratinocytes, perivascular lymphocytic 
infiltration and interface dermatitis in the absence of eosinophils. 
 
 7
Therapy of skin reactions 
All six patients required short-term hospitalizations and treatment for these skin reactions. 
The treatment consisted of supportive measures and various modalities during the 
hospitalization such as rest, avoidance of vigorous exercise and skin re-hydrating therapies. 
The medications included topic and systemic steroids, vitamin B6, topical antiseptic agents, 
urea 10 % ointment and emollient creams. These interventions led to a relief of the 
symptoms in all cases.  
Management and outcome 
Dose reduction was necessary in three patients, while only one patient was unable to 
continue the treatment due to painful skin eruptions and transient functional impairment. In 
one of the cases PPE presented at the end of the therapy with PLD (clinical case 1). Delays 
in administration of the chemotherapy for periods more than 1 week occurred in none of the 
patients. In one case an adjustment of the treatment intervals was required, and the time 
between the intravenous infusions of PLD 40 mg/m2 was increased from every two weeks to 
every four weeks. Two of the patients have died in the meantime. The patient described in 
case one, died of multiple organ failure due to septicaemia several months after developing 
PPE.  
Discussion 
PPE is the most common cumulative toxicity experienced by the patients treated with PLD 
and appears to be dose-interval related. In their study Lyass et al. evaluated different 
incidence of PPE among patients during various treatment schedules and doses. Shorter 
schedules of drug administration lead to more severe symptoms and greater toxicity, which 
is not related to the dosage of PLD given at each cycle. At the dose schedule of 35mg/ m2 
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administered every 3 weeks 17.7% of the patients developed PPE, while only 2.22% 
developed PPE at the dose of 50mg/ m2 every 4weeks and at the dose of 65mg/ m2 every 5 
weeks [13]. Wollina et al. resumed that of the 34 patients who received PLD in different 
dosages, grade 2 and 3 PPE was observed in only  5.88% and 2.94% of the patients 
respectively [11]. Two out of 3 patients who developed PPE were on a 2-week schedule. 
PPE was first reported in 1974 by Zuelke, during mitotane therapy [14]. It has been 
described that once PPE developes, can be recalled after treatment with other 
chemotherapeutic agents also known to cause this adverse effect [15]. It affects most 
commonly palms and soles, with hands being affected to a greater degree [16].  
It is intriguing that pre-existing skin disease may facilitate the involvement of skin areas, 
other than hand and feet, as we have seen in the patient with pre-diagnosed prurigo 
nodularis. Patient described in clinical case one, developed bullae and vesicles on the pre-
existing scars, which implies that compressed and damaged skin areas are faster and more 
intensely affected than normal skin. Preferential recruitment of liposomes to inflammateory 
areas was demonstrated in a murine model where liposomes were highly concentrated in 
areas around psoriatic lesion,which might be explained by the leakage of superficial post 
capillary venules in inflammatory areas [17]. 
In addition areas exposed to friction and to higher pressure such as axilla, groin, inner side of 
the knees, sacral area, bra line, elbow and wrist can be involved. This was also seen in the 
patient depicted in case one. The contribution of local trauma or pressure to the skin was 
reported in the study by Lyass et al [13]. PPE was manifestated in skin areas subjected to 
frequent contact pressure or microtrauma among 45 patients receiving PLD in different 
schedules and dosages, due to breast cancer [13].                                                                                                 
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Reduction of  the dose of PLD is a standard approach to eliminate the risk of PPE [18]. 
Patient’s education can also be very helpful [18]. Supportive treatment measures must start 
as soon as possible when the first signs of PLD adverse skin side effects occur, in order to 
relieve the symptoms and to avoid or/and reduce the severity of PPE [18]. Usually mild 
symptoms recede in one to three week. Non-pharmacologic interventions consist of sitting 
on padded surfaces, wearing loose clothing, and keeping the skin well hydrated. In addition  
avoidance of jogging or vigorous exercise and sunlight and use of regional cooling may have 
a positive effect in relieving the symptoms [19-21]. Emollients creams are of great value[22] 
while though corticosteroids and pyridoxine are used in clinical practice, their effects still 
remain to be cleared [23]. 
 The eruption of lymphocyte recovery concurs with the return of the lymphocytes to the 
peripheral circulation and skin. It occurs more commonly after bone marrow ablative 
antineoplastic chemotherapy in leukaemia patients with a decrease in WBC count at a febrile 
patient [24]. The diagnosis of ELR should be based on both clinical and histological 
findings, as both are not specific [25]. It is manifestated as a generalised macular or papular 
rash, which reveals a non specific dermatitis in the biopsy. The histological features of ELR 
consist of a scan moderate superficial perivascular mononuclear infiltrate consisting 
predominantly of T-cells, followed by mild epidermal changes including slight basal 
vacuolization, intercellular oedema, atypical keratinocytes and dysmaturation [26]. With this 
article we for the first time depict a case of ELR in connection with therapy with PLD. The 
differentiation between ELR from drug eruption is of great significance since patients are 
often given multiple essential drugs when the rash occurs, especially in regard of initiating 
appropriate therapeutic measures. 
Stomatitis was only present in one of the herewith presented patients, after two intravenous 
infusions of 85mg/m2 of PLD (clinical case 6). The severity of stomatitis correlates strongly 
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with the dose and maximum plasma concetration (Cmax) and it is most often seen  at doses 
around 60-70 mg/m2. In the report of Al Batran et al. 22 of 45 enrolled patients developed 
grade 1-4 mucositis [27]. In addition Hamilton et al. showed that the reduction in the dose of 
PLD by administering higher doses at prolonged intervals (i.e. 60-70 mg/ m2 every 6 weeks) 
was associated with significantly less PPE but higher rates of mucositis, ranging between 53 
to 100%, including grade 3-4 mucositis in 12,5-85 % of patients [28]. 
Intertrigo-like dermatitis describes the development of rather painful erythematous patches 
at areas of skin folding such as axilla, belt region, groin and waist and resembles the 
manifestations of intertrigo. A case of a 60-year old woman treated with PLD that developed 
erythema at her axilla and groin, compatible with intertrigo like dermatitis has also been 
reported. The biopsy revealed interface dermatitis with epidermal dysmaturation [29]. 
In literature other skin reactions also correlated with PLD treatment are described. Harrison 
et al. reported alopecia in 8.8% of 34 patients receiving treatment with liposomal 
doxorubucin due to Acquired Immune Deficiency Syndrome(AIDS) related Kaposi sarcoma  
while Uzielly et al. described no cases of alopecia in two separate phase I studies of 56 
patients [30] .Other skin manifestations of minor clinical significance include diffuse 
follicular rash, melanotic spots in unusual areas such as finger and toes webs, palms and 
soles, trunk, nail pigmentation, radiation- recall responses, hyperkeratosis and dry skin [13, 
31, 32]. 
Conclusion 
Pegylated liposomal doxorubicin induces various skin reactions including palmar plantar 
erythrodysesthesia syndrome. The exact clinical presentations might depend on pre-existing 
skin diseases. When skin reactions appear they may alter or affect patient’s quality of life. 
However, they often respond to dose reduction and do not usually limit the duration of the 
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therapy. Finally palmar plantar erythrodysesthesia syndrome is frequent among patients 
treated with liposomal doxorubucin and as a result all physicians should be familiar with its 
clinical and histological manifestations, so that they can easily distinguish it from allergic 
drug reactions. 
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 Table 1. Grading of skin lesions according to National Cancer Institute common toxicity 
criteria (NCI CTC) version 3  
Terminology Grade 1 Grade 2 Grade 3 Grade  4  Grade  5 
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Rash 
Desquamation 
Macular or 
papular 
eruption or 
erythema 
without 
associated 
symptoms 
Macular or 
papular eruption 
or erythema with 
pruritus or other 
associated 
symptoms. 
localized 
desquamation or 
other lesions 
covering <50% of 
body surface area 
(BSA) 
Severe, 
generalized 
erythroderma or 
macular papular 
or vesicular 
eruption; 
desquamation 
Covering> 50% 
BSA 
Generalised 
exfoliative, 
ulcerative or 
bullous 
dermatitis 
Death 
 
Table 2.  Patients’ demographic and clinical characteristics, dose intensity and impact of skin 
reactions on chemotherapy continuation. 
Patient       Age       PLD dose  Intervals  Localization  PPE grade Onset of toxicity  Consequences  Diagnosis   Other                
   No          in years    mg/m2         weeks                                           after Cycles                                                     observations 
  
1   71         100mg         4          S, I, P,C           IV              5                          -               PPE             PN                                           
2    40          50                    2           S, P, A, E        III 3            stop         ELR    
3   56          30          4           P, S               II 3            reduction             PPE 
4   72          40          2           P, S, T            II 2            prolongation        PPE             SG inv. 
5   56          50          4           I, E, P, S         III 3, 5                     reduction              PPE 
6   29          85          4           I, OM,            II               2                         reduction              ILD             Stom.             
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P palms, S soles, I intertriginous areas, A axilla, E extremities, OM oral mucosa, Capillitium, 
T thighs  
PPE        Palmar plantar erythrodysesthesia 
ELR       Eruption lymphocyte recovery 
Stom.     Stomatitis 
ILD        Intertrigo-like Dermatitis 
SG inv.  Sweat glands involvement 
PN         Prurigo nodularis 
PLD     Pegylated liposomal doxurubicin 
Fig.1 Grade IV PPE with bullous formation and erosions at the feet of Pat.1 
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Fig.2   Grade IV PPE with bullous formation, painful edema and desquamation at both hands 
of Pat.1 
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Fig.3.  Grade IV PPE with bullous formation and erosions on pre-existing scars at the trunk 
of Pat. 1 
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